FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386023526> ?p ?o ?g. }

• W4386023526 abstract "Abstract Objectives Inflammatory cytokines that signal through the JAK-STAT pathway, especially interferons (IFNs), are implicated in Sjögren’s Disease (SjD). Although inhibition of JAKs is effective in other autoimmune diseases, a systematic investigation of IFN-JAK-STAT signaling and effect of JAK inhibitor (JAKi) therapy in SjD-affected human tissues has not been reported. Methods Human minor salivary glands (MSGs) and peripheral blood mononuclear cells (PBMCs) were investigated using bulk or single cell (sc) RNA sequencing (RNAseq), immunofluorescence microscopy (IF), and flow cytometry. Ex vivo culture assays on PBMCs and primary salivary gland epithelial cell (pSGEC) lines were performed to model changes in target tissues before and after JAKi. Results RNAseq and IF showed activated JAK-STAT pathway in SjD MSGs. Elevated IFN-stimulated gene (ISGs) expression associated with clinical variables (e.g., focus scores, anti-SSA positivity). scRNAseq of MSGs exhibited cell-type specific upregulation of JAK-STAT and ISGs; PBMCs showed similar trends, including markedly upregulated ISGs in monocytes. Ex vivo studies showed elevated basal pSTAT levels in SjD MSGs and PBMCs that were corrected with JAKi. SjD-derived pSGECs exhibited higher basal ISG expressions and exaggerated responses to IFNβ, which were normalized by JAKi without cytotoxicity. Conclusions SjD patients’ tissues exhibit increased expression of ISGs and activation of the JAK-STAT pathway in a cell type-dependent manner. JAKi normalizes this aberrant signaling at the tissue level and in PBMCs, suggesting a putative viable therapy for SjD, targeting both glandular and extraglandular symptoms. Predicated on these data, a Phase Ib/IIa randomized controlled trial to treat SjD with tofacitinib was initiated. What is already known on this topic? Upregulation of interferons (IFNs) has been reported in patients with SjD; however, a systematic investigation of their role at a cellular and tissue level in humans is lacking. What this study adds? Our findings conclusively show that the IFN-JAK-STAT pathway is activated in the salivary glands and PBMCs in patients with SjD Specific cells in the MSGs (infiltrating lymphocytes, epithelial, antigen presenting cells, and endothelial cells) and in PBMCs (monocytes, NK cells, and dendritic cells) drive this IFN signature. We pinpoint cells responsive to JAK inhibition and illustrate in patient tissues that JAK inhibitors may be beneficial in SjD by uncoupling the pathogenic cytokine milieu and resultant epithelial tissue damage and dysfunction central to SjD. How this study might affect research, practice, or policy? SjD lacks an approved, efficacious and targeted therapy. Several large clinical trials have been unsuccessful due in part to a lack of biologically relevant endpoints or predictive biomarkers. We establish a multimodal testing platform using human tissues from SjD patients to identify actionable targets and to directly test treatment effects. Our data suggest that blocking the IFN-JAK-STAT pathway by using JAKi is a rational therapy for SjD. Moreover, these data can also serve as biological endpoints for clinical trials [ NCT04496960 ]." @default.
• W4386023526 created "2023-08-22" @default.
• W4386023526 creator A5001418105 @default.
• W4386023526 creator A5004951304 @default.
• W4386023526 creator A5006074713 @default.
• W4386023526 creator A5009698253 @default.
• W4386023526 creator A5010177366 @default.
• W4386023526 creator A5010407321 @default.
• W4386023526 creator A5018878859 @default.
• W4386023526 creator A5019378601 @default.
• W4386023526 creator A5024732306 @default.
• W4386023526 creator A5029770035 @default.
• W4386023526 creator A5035858921 @default.
• W4386023526 creator A5036061259 @default.
• W4386023526 creator A5038652272 @default.
• W4386023526 creator A5041450311 @default.
• W4386023526 creator A5042512946 @default.
• W4386023526 creator A5042747759 @default.
• W4386023526 creator A5050363088 @default.
• W4386023526 creator A5052248382 @default.
• W4386023526 creator A5053554949 @default.
• W4386023526 creator A5055846414 @default.
• W4386023526 creator A5059913903 @default.
• W4386023526 creator A5074670685 @default.
• W4386023526 creator A5083863078 @default.
• W4386023526 creator A5084474723 @default.
• W4386023526 creator A5092807098 @default.
• W4386023526 date "2023-08-21" @default.
• W4386023526 modified "2023-10-09" @default.
• W4386023526 title "Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren’s Disease" @default.
• W4386023526 cites W1720276080 @default.
• W4386023526 cites W1826391515 @default.
• W4386023526 cites W1965672602 @default.
• W4386023526 cites W1982148412 @default.
• W4386023526 cites W1991838482 @default.
• W4386023526 cites W2014330392 @default.
• W4386023526 cites W2015700502 @default.
• W4386023526 cites W2045651220 @default.
• W4386023526 cites W2069302785 @default.
• W4386023526 cites W2071830659 @default.
• W4386023526 cites W2077550414 @default.
• W4386023526 cites W2081634678 @default.
• W4386023526 cites W2084043206 @default.
• W4386023526 cites W2085221649 @default.
• W4386023526 cites W2087292563 @default.
• W4386023526 cites W2106273198 @default.
• W4386023526 cites W2117159031 @default.
• W4386023526 cites W2136811387 @default.
• W4386023526 cites W2171302007 @default.
• W4386023526 cites W2297563685 @default.
• W4386023526 cites W2344145904 @default.
• W4386023526 cites W2626892937 @default.
• W4386023526 cites W2767195935 @default.
• W4386023526 cites W2793352806 @default.
• W4386023526 cites W2916037465 @default.
• W4386023526 cites W2916230790 @default.
• W4386023526 cites W2939131851 @default.
• W4386023526 cites W2941355161 @default.
• W4386023526 cites W2964002548 @default.
• W4386023526 cites W2977976122 @default.
• W4386023526 cites W2981621278 @default.
• W4386023526 cites W2995626205 @default.
• W4386023526 cites W3009920944 @default.
• W4386023526 cites W3012113304 @default.
• W4386023526 cites W3022289262 @default.
• W4386023526 cites W3047864034 @default.
• W4386023526 cites W3109341372 @default.
• W4386023526 cites W3136549884 @default.
• W4386023526 cites W3137107306 @default.
• W4386023526 cites W3168601105 @default.
• W4386023526 cites W3174848623 @default.
• W4386023526 cites W3189760019 @default.
• W4386023526 cites W3196897371 @default.
• W4386023526 cites W4306926192 @default.
• W4386023526 cites W4322506025 @default.
• W4386023526 cites W896811953 @default.
• W4386023526 doi "https://doi.org/10.1101/2023.08.16.23294130" @default.
• W4386023526 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37662351" @default.
• W4386023526 hasPublicationYear "2023" @default.
• W4386023526 type Work @default.
• W4386023526 citedByCount "0" @default.
• W4386023526 crossrefType "posted-content" @default.
• W4386023526 hasAuthorship W4386023526A5001418105 @default.
• W4386023526 hasAuthorship W4386023526A5004951304 @default.
• W4386023526 hasAuthorship W4386023526A5006074713 @default.
• W4386023526 hasAuthorship W4386023526A5009698253 @default.
• W4386023526 hasAuthorship W4386023526A5010177366 @default.
• W4386023526 hasAuthorship W4386023526A5010407321 @default.
• W4386023526 hasAuthorship W4386023526A5018878859 @default.
• W4386023526 hasAuthorship W4386023526A5019378601 @default.
• W4386023526 hasAuthorship W4386023526A5024732306 @default.
• W4386023526 hasAuthorship W4386023526A5029770035 @default.
• W4386023526 hasAuthorship W4386023526A5035858921 @default.
• W4386023526 hasAuthorship W4386023526A5036061259 @default.
• W4386023526 hasAuthorship W4386023526A5038652272 @default.
• W4386023526 hasAuthorship W4386023526A5041450311 @default.
• W4386023526 hasAuthorship W4386023526A5042512946 @default.
• W4386023526 hasAuthorship W4386023526A5042747759 @default.
• W4386023526 hasAuthorship W4386023526A5050363088 @default.
• W4386023526 hasAuthorship W4386023526A5052248382 @default.

• next